Beigene Ltd to Post Q3 2018 Earnings of ($2.97) Per Share, Leerink Swann Forecasts (BGNE)
Beigene Ltd (NASDAQ:BGNE) – Research analysts at Leerink Swann issued their Q3 2018 earnings estimates for shares of Beigene in a research report issued on Monday, September 24th. Leerink Swann analyst A. Berens anticipates that the company will post earnings of ($2.97) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $215.00 target price on the stock. Leerink Swann also issued estimates for Beigene’s Q4 2018 earnings at ($3.19) EPS, FY2018 earnings at ($11.15) EPS, FY2019 earnings at ($11.37) EPS, FY2020 earnings at ($11.27) EPS, FY2021 earnings at ($6.32) EPS and FY2022 earnings at $1.99 EPS.
Beigene (NASDAQ:BGNE) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($2.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.12) by ($0.80). The business had revenue of $52.80 million during the quarter, compared to analyst estimates of $22.53 million. Beigene had a negative return on equity of 24.14% and a negative net margin of 75.19%. The company’s quarterly revenue was up 5279999900.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.52) EPS.
Beigene stock opened at $172.03 on Thursday. The company has a current ratio of 8.14, a quick ratio of 8.10 and a debt-to-equity ratio of 0.16. Beigene has a 1 year low of $77.54 and a 1 year high of $220.10.
In other news, CMO Jane Huang sold 2,911 shares of the business’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $174.60, for a total transaction of $508,260.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO John Oyler sold 2,550 shares of the business’s stock in a transaction on Monday, July 16th. The shares were sold at an average price of $164.12, for a total transaction of $418,506.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,679 shares of company stock worth $2,808,018. 14.10% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. Northern Trust Corp grew its holdings in shares of Beigene by 25.2% during the 2nd quarter. Northern Trust Corp now owns 2,250 shares of the company’s stock valued at $346,000 after acquiring an additional 453 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Beigene during the 2nd quarter valued at $1,837,000. Millennium Management LLC grew its holdings in shares of Beigene by 560.7% during the 2nd quarter. Millennium Management LLC now owns 132,139 shares of the company’s stock valued at $20,314,000 after acquiring an additional 112,139 shares in the last quarter. Waddell & Reed Financial Inc. grew its holdings in shares of Beigene by 11.3% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 158,170 shares of the company’s stock valued at $24,315,000 after acquiring an additional 16,080 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Beigene by 5,558.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 679 shares of the company’s stock valued at $104,000 after acquiring an additional 667 shares in the last quarter. Institutional investors and hedge funds own 77.87% of the company’s stock.
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Featured Article: Stock Split
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.